Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director · Executive Chair | March 17, 2021 | March 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Tempest Therapeutics, Inc.
Report date March 17, 2021 · Filed March 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2031-03-16 | Direct | 24,000 |
Reported balance
After 2021-03-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-17 · Grant · Acquired 24,000 · Balance 24,000 F1: One-third (1/3) of the shares subject to this option shall vest on February 1, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3) of the shares subject to this option shall vest on February 1, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2022 Filed Sep 6, 2022 19:24 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001209191-22-048883 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| May 24, 2021 Filed May 25, 2021 18:56 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-21-035777 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-05-23 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:11 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001209191-21-025123 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in 36 equal monthly installments from the Vesting Commencement Date of April 1, 2021, subject to Reporting Person providing continuous service through such date. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 16:47 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001544227-21-000013 · wf-form4_161618685991338.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-03-16 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to this option shall vest on February 1, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. Read SEC document |
| May 25, 2020 Filed May 27, 2020 21:34 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 282,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032485 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 282,000 shares Expires 2030-05-24 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:32 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001209191-20-006367 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 7, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:40 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 76,007 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-038488 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,007 Underlying: Common Stock · 76,007 shares Expires 2029-06-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:50 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 173,993 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004245 · doc4.xml · derivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,993 Underlying: Common Stock · 173,993 shares Expires 2029-01-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:49 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 174,839 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-062126 · doc4.xml · derivative · entry 4 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,839 Underlying: Common Stock · 174,839 shares Expires 2028-08-23 F7 · price: Received in connection with the Merger in exchange for a stock option to acquire 2,350,000 shares of Millendo common stock for $1.22 per share. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:49 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 151,600 | Not disclosed Strike: $4.44 | Not disclosed |
DisclosureSEC source: 0001209191-18-062126 · doc4.xml · derivative · entry 3 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,600 Underlying: Common Stock · 151,600 shares Expires 2026-01-27 F5 · price: Received in connection with the Merger in exchange for a stock option to acquire 2,037,648 shares of Millendo common stock for $0.33 per share. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on January 28, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:49 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 60,179 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001209191-18-062126 · doc4.xml · derivative · entry 2 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,179 Underlying: Common Stock · 60,179 shares Expires 2022-08-29 F3 · price: Received in connection with the Merger in exchange for a stock option to acquire 808,867 shares of Millendo common stock for $0.08 per share. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:49 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantCommon Stock | 74,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-062126 · doc4.xml · nonDerivative · entry 1 Owens Julia C. · CIK 0001760219 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,400 F1 · price: Received in exchange for 1,000,000 shares of Millendo Therapeutics, Inc. ("Millendo") common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.